Metabolic syndrome.
Conditions
Interventions
Intervention 1: Intervention group: People in this group take Resveratrol (An active compound of acetylene phytoalexin) capsule supplements once a day before meals for a month. Intervention 2: Control
Sponsors
Qazvin University of Medical Sciences
Eligibility
Sex/Gender
All
Age
18 Years to 50 Years
Inclusion criteria
Inclusion criteria: People between 18 to 50 years old Complete consent of individuals to participate in the study Having a BMI of 25 to 30 kg/m²
Exclusion criteria
Exclusion criteria: People having any allergies to the drug People with diabetes People with a history of high fat under treatment People taking vitamins and supplements People taking herbal medicines Patients with a history of inflammatory disease being treated People with known liver and kidney disease People with known lipid disease People treated with corticosteroids, aspirin and anti-lipids and hormonal drugs, hyperthyroidism and hypothyroidism People on drug treatment related to metabolic syndrome
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Measurement of fasting Insulin. Timepoint: Before starting intervention and one month after intervention. Method of measurement: At the beginning and end of the study, it will be measured by Snible kit.;Measuring the mass of fat accumulated in the body. Timepoint: Before starting intervention and one month after intervention. Method of measurement: At the beginning and end of the study, the amount of accumulated fat will be measured with a digital scale.;Measurement of Follicle Stimulating Hormone. Timepoint: Before starting intervention and one month after intervention. Method of measurement: At the beginning and end of the study, it will be measured by Snible kit.;Measurement of Luteinizing hormone. Timepoint: Before starting intervention and one month after intervention. Method of measurement: At the beginning and end of the study, it will be measured by Snible kit.;Measurement of Dehydroepiandroterone. Timepoint: Before starting intervention and one month after intervention. Method of measurement: At the beginning and end of the study, it will be measured by Snible kit.;Measurement of Anti Mullerian hormone. Timepoint: Before starting intervention and one month after intervention. Method of measurement: At the beginning and end of the study, it will be measured by kit.;Measurement of Insulin-like growth factor 1. Timepoint: Before starting intervention and one month after intervention. Method of measurement: At the beginning and end of the study, it will be measured by kit.;Measurement of Interleukin 6. Timepoint: Before starting intervention and one month after intervention. Method of measurement: At the beginning and end of the study, it will be measured by kit.;Measurement of Self-monitoring of blood glucose. Timepoint: Before starting intervention and one month after intervention. Method of measurement: At the beginning and end of the study, it will be measured by kit.;Measurement of Testosterone. Timepoint: Before starting intervention and one month after | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactDr. Nematollah Gheibi
Qazvin University of Medical Sciences
Outcome results
None listed